Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Integra to develop modified artificial skin:

This article was originally published in Clinica

Executive Summary

Integra Life Sciences has received a $250,000 grant from the US National Institutes of Health to develop an RGD-peptide modified version of its INTEGRA artificial skin, a tissue-engineered product used to treat full-thickness burns and other skin injuries. Early pre-clinical trials indicated that the peptide-enhanced product could accelerate angiogenesis and lead to a faster rate of healing, said the Plainsboro, New Jersey-based company. Integra also received a recommendation for a Phase II grant worth $1.5 million, subject to satisfactory completion of the Phase I programme and certain other conditions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel